Impaired antibody-mediated protection and defective iga b-cell memory in experimental infection of adults with respiratory syncytial virus

American Journal of Respiratory and Critical Care Medicine

Volumn 191, Issue 9, 2015, Pages 1040-1049

  Habibi, Maximillian S ^a   Jozwik, Agnieszka ^a   Makris, Spyridon ^a   Dunning, Jake ^a   Paras, Allan ^a   DeVincenzo, John P ^b   De Haan, Cornelis A M ^c   Wrammert, Jens ^d,e   Openshaw, Peter J M ^a   Chiu, Christopher ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UTRECHT UNIVERSITY   (Netherlands)

^d Department of Pediatric Infectious Disease ^*  (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody secreting cells; Immunologic memory; Mucosal immunity; Nontherapeutic human experimentation; Respiratory syncytial virus vaccines

Indexed keywords

B CELL ACTIVATING FACTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 15; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY SECRETING CELL; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CONVALESCENCE; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EXPERIMENTAL INFECTION; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN RESPIRATORY SYNCYTIAL VIRUS; HUMORAL IMMUNITY; IN VITRO STUDY; INOCULATION; MALE; MEMORY CELL; NONHUMAN; NORMAL HUMAN; NOSE SECRETION; PLASMABLAST; POLYCLONAL ACTIVATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT INFECTION; REINFECTION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS SHEDDING; ADOLESCENT; CLINICAL TRIAL; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; B-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; YOUNG ADULT;

EID: 84929017747     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201412-2256OC     Document Type: Article

References (56)

1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010;375: 1545-1555.
2. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005;352:1749-1759.
3. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol 2002;76:5654-5666.
4. Gardner PS, McQuillin J, Court SDM. Speculation on pathogenesis in death from respiratory syncytial virus infection. BMJ 1970;1:327-330.
5. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991;163:693-698.
6. Okamoto M, Sugawara K, Takashita E, Muraki Y, Hongo S, Nishimura H, Matsuzaki Y. Longitudinal course of human metapneumovirus antibody titers and reinfection in healthy adults. J Med Virol 2010;82:2092-2096.
7. Glezen WP, Frank AL, Taber LH, Kasel JA. Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children. J Infect Dis 1984;150:851-857.
8. PATH. 2014. Respiratory syncytial virus: vaccine development against a major cause of childhood respiratory illness [accessed 2014 Dec 16]. Available from: http://sites.path.org/vaccinedevelopment/respiratory-syncytial-virus-rsv/.
9. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-537.
10. Falsey AR, Walsh EE. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J Infect Dis 1998;177:463-466.
11. Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP. Correlates of immunity to respiratory syncytial virus (RSV) associatedhospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 2003;21:3479-3482.
12. Bem RA, Domachowske JB, Rosenberg HF. Animal models of human respiratory syncytial virus disease. Am J Physiol Lung Cell Mol Physiol 2011;301:L148-L156.
13. DeVincenzo JP, Wilkinson T, Vaishnaw A, Cehelsky J, Meyers R, Nochur S, Harrison L, Meeking P, Mann A, Moane E, et al. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med 2010;182: 1305-1314.
14. Pollard AJ, Savulescu J, Oxford J, Hill AV, Levine MM, Lewis DJ, Read RC, Graham DY, Sun W, Openshaw P, et al. Human microbial challenge: the ultimate animal model. Lancet Infect Dis 2012;12: 903-905.
15. Chiu C, Habibi MS, Jozwik A, Paras A, Makris S, Openshaw PJM. B cell responses following experimental RSV challenge in adult volunteers. Presented at the RSV Vaccines for the World conference. October 14-16, 2013, Porto, Portugal.
16. Habibi MS, Jozwik A, Makris S, Paras A, Openshaw P, Chiu C. Human B cell responses following experimental respiratory syncytial virus challenge. Presented at the Controlled Human Infection Studies in the Development of Vaccines and Therapeutics conference. January 9-11, 2013, Cambridge, UK.
17. Habibi MS, Guvenel AK, Jozwik A, Paras A, Chiu C, Openshaw PJM. Immunity to respiratory syncytial virus (RSV) infection. Presented at the Keystone Symposia Meeting on Pathogenesis of Respiratory Viruses (J5), January 19-24, 2014, Keystone, CO.
18. Habibi MS, Jozwik A, Makris S, Dunning J, Paras A, Wrammert J, Openshaw PJM, Chiu C. Defective IgA B cell memory generation following experimental human respiratory syncytial virus infection impairs protective immunity. Presented at the 9th International Respiratory Syncytial Virus Symposium. Stellenbosch, South Africa, November 9-13, 2014.
19. Medrano González L, Habibi MS, Jozwik A, Openshaw PJM, Chiu C. Quality of antigen-specific B cell responses as a correlate of protection against RSV [abstract]. Immunology 2014;143:75.
20. Yang DP, Zielinska E, Quiroz J, Madore D, Rappaport R. Preparation of a respiratory syncytial virus human reference serum for use in the quantitation of neutralization antibody. Biologicals 2007;35:183-187.
21. Rennard SI, Basset G, Lecossier D, O'Donnell KM, Pinkston P, Martin PG, Crystal RG. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol (1985) 1986;60:532-538.
22. Saletti G, Çuburu N, Yang JS, Dey A, Czerkinsky C. Enzyme-linked immunospot assays for direct ex vivo measurement of vaccineinduced human humoral immune responses in blood. Nat Protoc 2013;8:1073-1087.
23. Crotty S, Aubert RD, Glidewell J, Ahmed R. Tracking human antigenspecific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods 2004;286:111-122.
24. Tengvall S, Lundgren A, Quiding-Järbrink M, Svennerholm A-M. BAFF, stimulatory DNA and IL-15 stimulates IgA(1) memory B cells and provides a novel approach for analysis of memory responses to mucosal vaccines. Vaccine 2010;28:5445-5450.
25. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013 [accessed 2014 Jan 21]. Available from: http://www.R-project.org/.
26. Sarkar D. Lattice: multivariate data visualization with R. New York: Springer; 2008 [accessed 2014 Apr 1]. Available from: http://lmdvr.r-forge.r-project.org.
27. Ritz C, Streibig JC. Bioassay analysis using R. J Stat Softw 2005;12:1-22.
28. Falsey AR, Singh HK, Walsh EE. Serum antibody decay in adults following natural respiratory syncytial virus infection. J Med Virol 2006;78:1493-1497.
29. Sande CJ, Mutunga MN, Okiro EA, Medley GF, Cane PA, Nokes DJ. Kinetics of the neutralizing antibody response to respiratory syncytial virus infections in a birth cohort. J Med Virol 2013;85:2020-2025.
30. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, Zheng N-Y, Mays I, Garman L, Helms C, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008; 453:667-671.
31. Wrammert J, Koutsonanos D, Li G-M, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011;208:181-193.
32. Li G-M, Chiu C, Wrammert J, McCausland M, Andrews SF, Zheng N-Y, Lee J-H, Huang M, Qu X, Edupuganti S, et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci USA 2012;109:9047-9052.
33. Wrammert J, Onlamoon N, Akondy RS, Perng GC, Polsrila K, Chandele A, Kwissa M, Pulendran B, Wilson PC, Wittawatmongkol O, et al. Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans. J Virol 2012;86:2911-2918.
34. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007;357: 1903-1915.
35. Mills JV, Van Kirk JE, Wright PF, Chanock RM, Fishburne IE. Experimental respiratory syncytial virus infection of adults: possible mechanisms of resistance to infection and illness. J Immunol 1971; 107:123-130.
36. Watt PJ, Robinson BS, Pringle CR, Tyrrell DA. Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines. Vaccine 1990;8:231-236.
37. Walsh EE, Falsey AR. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis 2004;190:373-378.
38. Lee FE-H, Walsh EE, Falsey AR, Betts RF, Treanor JJ. Experimental infection of humans with A2 respiratory syncytial virus. Antiviral Res 2004;63:191-196.
39. Fujimoto C, Takeda N, Matsunaga A, Sawada A, Tanaka T, Kimoto T, Shinahara W, Sawabuchi T, Yamaguchi M, Hayama M, et al. Induction and maintenance of anti-influenza antigen-specific nasal secretory IgA levels and serum IgG levels after influenza infection in adults. Influenza Other Respi Viruses 2012;6:396-403.
40. Barclay WS, al-Nakib W, Higgins PG, Tyrrell DA. The time course of the humoral immune response to rhinovirus infection. Epidemiol Infect 1989;103:659-669.
41. Lee FE-H, Falsey AR, Halliley JL, Sanz I, Walsh EE. Circulating antibody-secreting cells during acute respiratory syncytial virus infection in adults. J Infect Dis 2010;202:1659-1666.
42. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998;8:363-372.
43. Manz RA, Hauser AE, Hiepe F, Radbruch A. Maintenance of serum antibody levels. Annu Rev Immunol 2005;23:367-386.
44. Mora JR, von Andrian UH. Differentiation and homing of IgA-secreting cells. Mucosal Immunol 2008;1:96-109.
45. Mora JR, Iwata M, Eksteen B, Song S-Y, Junt T, Senman B, Otipoby KL, Yokota A, Takeuchi H, Ricciardi-Castagnoli P, et al. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science 2006;314:1157-1160.
46. He B, Xu W, Santini PA, Polydorides AD, Chiu A, Estrella J, Shan M, Chadburn A, Villanacci V, Plebani A, et al. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity 2007;26: 812-826.
47. Cerutti A, Chen K, Chorny A. Immunoglobulin responses at the mucosal interface. Annu Rev Immunol 2011;29:273-293.
48. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 2007;25:5467-5484.
49. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011; 29:621-663.
50. Cazac BB, Roes J. TGF-beta receptor controls B cell responsiveness and induction of IgA in vivo. Immunity 2000;13:443-451.
51. Borsutzky S, Cazac BB, Roes J, Guzmán CA. TGF-beta receptor signaling is critical for mucosal IgA responses. J Immunol 2004;173: 3305-3309.
52. Harris AM, Bhuiyan MS, Chowdhury F, Khan AI, Hossain A, Kendall EA, Rahman A, LaRocque RC, Wrammert J, Ryan ET, et al. Antigenspecific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh. Infect Immun 2009;77:3850-3856.
53. Clements ML, Murphy BR. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol 1986;23:66-72.
54. McNamara PS, Fonceca AM, Howarth D, Correia JB, Slupsky JR, Trinick RE, Al Turaiki W, Smyth RL, Flanagan BF. Respiratory syncytial virus infection of airway epithelial cells, in vivo and in vitro, supports pulmonary antibody responses by inducing expression of the B cell differentiation factor BAFF. Thorax 2013;68:76-81.
55. Openshaw PJ, Chiu C. Protective and dysregulated T cell immunity in RSV infection. Curr Opin Virol 2013;3:468-474.
56. Karron RA, Buchholz UJ, Collins PL. Live-attenuated respiratory syncytial virus vaccines. Curr Top Microbiol Immunol 2013;372:259-284.